Indapta Therapeutics Granted FDA Fast Track Designation for Natural Killer Cell Therapy for Hematologic Malignancies

Indapta Therapeutics has received FDA Fast Track Designation for its natural killer (NK) cell therapy IDP-023 for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). The company’s universal, allogeneic NK cell therapy platform is comprised of a potent subset of naturally occurring NK cells called G minus NK (g-NK) cells.

Read full article